Literature DB >> 20927322

Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model.

Sadhak Sengupta1, Suvobroto Nandi, Enal S Hindi, Derek A Wainwright, Yu Han, Maciej S Lesniak.   

Abstract

Glioblastoma multiforme is the most common and lethal primary brain tumor. Glioma progression depends on the rapid proliferation of tumor cells accompanied by an acute immunosuppressive environment, facilitated mainly by tumor infiltration of regulatory T cells (Tregs). In this study, we characterize the role of fibronectin, a high-molecular weight extracellular matrix glycoprotein secreted by tumor cells, in controlling glioma progression and in mediating immunosuppression. Fibronectin binds to membrane-spanning integrin receptors and plays an important role in cell signaling, in defining cellular shape, in mobility, and in regulating the cell cycle. We found that inhibition of fibronectin expression in glioma cells, using short hairpin RNA-mediated silencing of gene expression, delayed cell proliferation in vitro. This delayed growth is explained, in part, by the observed reduced expression of integrin β(1) fibronectin receptor, which was restored by the inhibition of proteosomal activity. In our analysis of the downstream signaling targets of integrin β(1), we demonstrated reduced phosphorylation of Src kinase and STAT-3. We also observed reduced survivin expression that induced a three-fold increased accumulation of fibronectin-knockdown cells in the G(2)/M phase. In an experimental animal model, the fibronectin knockdown tumors had a mean survival advantage of 23 days over wild-type tumors. Moreover, brain samples of animals bearing fibronectin-knockdown tumors showed delayed Treg recruitment. Collectively, we propose that fibronectin is a key mediator of glioma progression because its inhibition delays both tumor progression and immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20927322      PMCID: PMC2950333          DOI: 10.1593/neo.10662

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  50 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells.

Authors:  Shaik Ohidar Rahaman; Phyllis C Harbor; Olga Chernova; Gene H Barnett; Michael A Vogelbaum; S Jaharul Haque
Journal:  Oncogene       Date:  2002-12-05       Impact factor: 9.867

3.  Activation and association of Stat3 with Src in v-Src-transformed cell lines.

Authors:  X Cao; A Tay; G R Guy; Y H Tan
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

4.  Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA.

Authors:  Liying Cai; Guangmei Zhang; Xiaojing Tong; Qi You; Yuan An; Yuguang Wang; Lei Guo; Tianzhen Wang; Daling Zhu; Jianhua Zheng
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-01       Impact factor: 2.435

5.  The role of integrin receptors in aspects of glioma invasion in vitro.

Authors:  H K Rooprai; T Vanmeter; C Panou; S Schnüll; G Trillo-Pazos; D Davies; G J Pilkington
Journal:  Int J Dev Neurosci       Date:  1999 Aug-Oct       Impact factor: 2.457

6.  Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

Authors:  Guilian Niu; Tammy Bowman; Mei Huang; Steve Shivers; Douglas Reintgen; Adil Daud; Alfred Chang; Alan Kraker; Richard Jove; Hua Yu
Journal:  Oncogene       Date:  2002-10-10       Impact factor: 9.867

7.  Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation.

Authors:  A Suzuki; M Hayashida; T Ito; H Kawano; T Nakano; M Miura; K Akahane; K Shiraki
Journal:  Oncogene       Date:  2000-07-06       Impact factor: 9.867

8.  A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.

Authors:  S Farzana Hussain; Ling-Yuan Kong; Justin Jordan; Charles Conrad; Timothy Madden; Isabella Fokt; Waldemar Priebe; Amy B Heimberger
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

Review 9.  Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas.

Authors:  Emily C Brantley; Etty N Benveniste
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

Review 10.  EGFRvIII-targeted vaccination therapy of malignant glioma.

Authors:  Bryan D Choi; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Roger E McLendon; Darell D Bigner; John H Sampson
Journal:  Brain Pathol       Date:  2009-10       Impact factor: 6.508

View more
  24 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma.

Authors:  Ying Jing; Deshui Jia; Chun-Ming Wong; Irene Oi-Lin Ng; Zhenfeng Zhang; Li Liu; Qifeng Wang; Fangyu Zhao; Jinjun Li; Ming Yao; Xingzhong Wu; Xianghuo He
Journal:  Mol Oncol       Date:  2013-12-18       Impact factor: 6.603

3.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

4.  Prognostic value of members of NFAT family for pan-cancer and a prediction model based on NFAT2 in bladder cancer.

Authors:  Zhou-Tong Dai; Yuan Xiang; Yundan Wang; Le-Yuan Bao; Jun Wang; Jia-Peng Li; Hui-Min Zhang; Zhongxin Lu; Sreenivasan Ponnambalam; Xing-Hua Liao
Journal:  Aging (Albany NY)       Date:  2021-05-07       Impact factor: 5.682

5.  Tumor cohesion and glioblastoma cell dispersal.

Authors:  Ramsey A Foty
Journal:  Future Oncol       Date:  2013-08       Impact factor: 3.404

6.  Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.

Authors:  Hilary A Kenny; Chun-Yi Chiang; Erin A White; Elizabeth M Schryver; Mohammed Habis; Iris L Romero; Andras Ladanyi; Carla V Penicka; Joshy George; Karl Matlin; Anthony Montag; Kristen Wroblewski; S Diane Yamada; Andrew P Mazar; David Bowtell; Ernst Lengyel
Journal:  J Clin Invest       Date:  2014-09-09       Impact factor: 14.808

7.  Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury.

Authors:  Rachel N Andrews; David L Caudell; Linda J Metheny-Barlow; Ann M Peiffer; Janet A Tooze; J Daniel Bourland; Robert E Hampson; Samuel A Deadwyler; J Mark Cline
Journal:  Radiat Res       Date:  2018-07-17       Impact factor: 2.841

8.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

Review 9.  Recent developments on immunotherapy for brain cancer.

Authors:  Derek A Wainwright; Pragati Nigam; Bart Thaci; Mahua Dey; Maciej S Lesniak
Journal:  Expert Opin Emerg Drugs       Date:  2012-04-25       Impact factor: 4.191

10.  Fibronectin 1: A Potential Biomarker for Ovarian Cancer.

Authors:  Huijing Bao; Qianyu Huo; Qin Yuan; Chen Xu
Journal:  Dis Markers       Date:  2021-05-22       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.